BioAge Labs (BIOA) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
1 of 2 scored quarters beat.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026press release, after close · 4:30 pm ET | −0.63 | −0.73 | −15.0% | $1.5M | $298,000.00 | −79.8% | −3.6%next session |
| Aug 5, 20268-K, after close · 4:55 pm ET | −0.61 | −0.58 | +4.5% | $1.5M | $2.5M | +63.7% | +2.6%next session |
| May 8, 20268-K, before open · 9:10 am ET | — | −0.52 | — | — | $2.8M | — | +1.0%release day |
| Mar 24, 20268-K, before open · 9:10 am ET | — | −0.72 | — | — | $3.1M | — | −13.5%release day |
| Nov 6, 20258-K, after close · 4:50 pm ET | — | −0.56 | — | — | $2.1M | — | −2.8%next session |
| Aug 6, 20258-K, after close · 4:35 pm ET | — | −0.60 | — | — | $2.4M | — | −0.2%next session |
| May 6, 20258-K, after close · 4:35 pm ET | — | −0.36 | — | — | $1.5M | — | +2.8%next session |
| Mar 20, 20258-K, after close · 4:54 pm ET | — | 15.77 | — | — | — | — | +2.5%next session |
Estimate-vs-actual scoring began Jul 2026 and is still accruing: 2 of the 8 quarters above carry a scored estimate. We never backfill an estimate we didn't observe.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 6 | 4 | 6 | 7 |
| Avg estimate | −0.74 | −0.66 | −2.59 | −2.52 |
| Low estimate | −0.80 | −0.72 | −2.68 | −2.80 |
| High estimate | −0.69 | −0.54 | −2.51 | −2.08 |
| Year-ago EPS | −0.72 | −0.52 | −2.24 | −2.59E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 6 | 2 | 9 | 8 |
| Avg estimate | $965,111.00 | $287,500.00 | $6.5M | $7.2M |
| Low estimate | $536,172.00 | $219,852.00 | $6.0M | $470,975.00 |
| High estimate | $1.4M | $355,147.00 | $7.4M | $11.8M |
| Year-ago revenue | $3.1M | $2.8M | $9.0M | $6.5ME |
| Implied growth | −68.6% | −89.6% | −27.5% | +9.9% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.74 | −0.66 | −2.59 | −2.52 |
| 7 days ago | −0.68 | — | −2.46 | −2.26 |
| 30 days ago | −0.68 | — | −2.46 | −2.26 |
| 60 days ago | −0.66 | — | −2.43 | −2.17 |
| 90 days ago | −0.69 | — | −2.51 | −2.09 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $−0.69 → $−0.74 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were BioAge Labs' latest quarterly earnings?
BioAge Labs reported diluted EPS of −0.73 and revenue of $298,000.00 on Nov 5, 2026.
How did BioAge Labs' stock move after its last earnings report?
BioAge Labs moved −3.6% in the session after its Nov 5, 2026 report.

